Business Context and Reporting Period
This Form 8-K is a Current Report filed by BioSig Technologies, Inc. (BSGM) on July 26, 2021. The filing discloses the key findings of the PURE EP 2.0 multi-center clinical study and the completion of enrollment in the Re-Do Atrial Fibrillation Ablation Study. The company develops cardiac mapping systems, specifically the PURE EP system, to assist in cardiac ablation procedures.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and regulatory disclosures rather than financial performance data.
Material Changes and Clinical Results
The primary material event is the announcement of the PURE EP 2.0 study results involving 51 patients across three major medical centers. Key findings include:
- Overall Performance: PURE EP signals were rated superior or equivalent 94% of the time compared to conventional sources.
- Signal Quality: 92% of signals were rated superior or equivalent in overall quality.
- Signal Discrimination: 96% of signals were rated superior or equivalent for discerning near-field versus far-field cardiac signals.
- Fractionated Signals: 95% of small, fractionated signals of clinical interest were rated superior or equivalent.
- Statistical Superiority: Data was rated as statistically superior in all types of ablation procedures.
Additionally, the company completed enrollment in the Re-Do Atrial Fibrillation Ablation Study with 20 patients. Results for this study are expected in early 2022.
Guidance, Outlook, and Risks
The company expects the PURE EP 2.0 study data to be reviewed for publication. The Re-Do Atrial Fibrillation Ablation Study results are anticipated in early 2022. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks including:
- Impact of COVID-19 on business operations and capital raising.
- Inability to manufacture products on a commercial scale.
- Difficulties in obtaining financing on commercially reasonable terms.
- Changes in competition and loss of key personnel.
- Difficulties in securing regulatory approval.
Investor Verification Checklist
- Verify the publication status of the PURE EP 2.0 study data in peer-reviewed journals.
- Monitor the timeline for the release of the Re-Do Atrial Fibrillation Ablation Study results (expected early 2022).
- Review the company's most recent 10-K and 10-Q filings for financial health, cash runway, and debt levels, as this 8-K contains no financial data.
- Assess the company's progress toward regulatory approval for commercialization of the PURE EP system.
- Confirm the company's ability to secure future financing given the stated risks regarding capital raising.